Inspired by antibodies found in long-term leukemia survivors, a novel selective CAR T approach eliminated AML in preclinical ...
In fact, once Health Canada approves a drug, the process should skip Canada’s Drug Agency entirely. The CDA is a bureaucratic ...
The FDA on Wednesday approved a new all-oral regimen for newly diagnosed acute myeloid leukemia (AML) in patients ineligible ...
A limitation to cancer treatment, specifically acute myeloid leukemia (AML) is the ability to effectively target tumors cells ...
Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep ...
Regulatory clearance creates an at-home, 28-day cycle option using oral decitabine/cedazuridine on days 1–5 plus venetoclax 400 mg daily after a ramp-up cycle. Efficacy signals in ASCERTAIN-V included ...
FDA authorized decitabine/cedazuridine plus venetoclax as the first all-oral HMA/BCL-2 regimen for newly diagnosed AML patients unfit for intensive induction chemotherapy. ASCERTAIN-V enrolled 101 ...
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers and is characterized by the rapid growth of immature ...
Andrea Brault is fighting acute myeloid leukemia and needs a bone marrow transplant. But finding a donor match can be more ...
COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will announce the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results